✦ LIBER ✦

Double-platinum chemotherapy combined with etoposide in metastatic brain tumor from small cell lung carcinoma

✍ Scribed by Shoko M. Yamada; Shokei Yamada; Hiroshi Takahashi; Akira Teramoto; Hitoshi Nakayama

Book ID: 106480081
Publisher: Springer US
Year: 2005
Tongue: English
Weight: 695 KB
Volume: 71
Category: Article
ISSN: 0167-594X
DOI: 10.1007/s11060-004-1393-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy with bleomycin,

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Combination chemotherapy with cisplatin,

Combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung carcinoma (SCLC)

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 87 KB

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

ERCC1 expression in circulating tumor ce

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

✍ Das, Millie; Riess, Jonathan W.; Frankel, Paul; Schwartz, Erich; Bennis, Robyn; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 482 KB

2 Quality of life assessment in the elde

2 Quality of life assessment in the elderly population (above 70 years of age) with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with a platinum-based combination-chemotherapy regimen

✍ Bæksgaard, L.; Henriksen, A.; Hasselbalch, B.; Dandanell, J.; Perell, K.; Sørens 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 78 KB

PCN67 LOWER ADMINISTRATION COSTS OF BEVA

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

✍ H Rosery; C Castro de; H Bischoff; D Heigener; A Vergnenegre; C Chouaid; S Walze 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB